Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ICI201 in Relapsed/Refractory Multiple Myeloma
NCT05980507Phase 1Withdrawn
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2023
- Primary completion
- Oct 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICI-201 in multiple myeloma (MM), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Dose Limiting Toxicity at 28 days and Incidence and Severity of Adverse Events at 2 years. Planned start Oct 2023; status: withdrawn.
02
Drugs
ICI-201
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05980507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05980507.